Jupiter Endovascular, Inc., a medical technology startup transforming endovascular medicine with a new class of interventions, announced today that experienced medtech finance and operations executive Fred Ong has joined the company as Chief Financial Officer.
Fred Ong brings more than 30 years of experience in building and growing venture capital-backed healthcare technology companies to his role at Jupiter Endovascular, including playing key roles in fundraising, corporate strategy, operational growth, revenue scale, and M&A exits. He has served as Chief Financial Officer for Sirona Medical, Datavant, and U-Systems, and was instrumental in the successful exits of several companies by acquisition and merger with larger strategics.
“I’m thrilled to join the Jupiter Endovascular team as they continue to execute on their mission to transform endovascular therapy with their groundbreaking transcatheter technology,” said Ong. “It is exciting to see their early clinical success in addressing pulmonary embolism, and the enormous potential of this technology to meaningfully improve the physician experience and patient outcomes. I look forward to playing a role in advancing the company from its current clinical stage through commercialization. With a strong and expanding base of intellectual property, there is tremendous opportunity across a variety of disease conditions and procedures to grow applications for the technology into the future.”
“We are delighted to welcome Fred to Jupiter, and look forward to his significant contribution to the company’s success moving forward,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “Fred is joining us at a pivotal time as we build upon our strong clinical momentum in pulmonary embolism and continue to grow, expand, and prepare for what we believe is a robust commercial opportunity for our transformational technology.”
The company’s Endoportal Control™ platform technology is designed to bring greater ease and stability to a variety of catheter interventions, with the goal of enabling interventionalists to treat anatomical sites that they cannot safely or easily reach with a conventional endovascular approach. The endoportal device is delivered in a flexible, relaxed state over a guidewire to a target location in the vasculature, pressurized with saline to fix it in a stable position for therapeutic delivery, then relaxed again to navigate to another target location or for removal.
In recent months, the company began enrolling patients in a U.S. pivotal study of its technology in acute, intermediate-risk pulmonary embolism. The company exited stealth mode in August 2024 with $21 million in financing.
